Hyundai Bioscience Q1 FY2027: Widening Losses Amid Clinical Progress

Consolidated revenue of 0.3B KRW (54% YoY decline), operating loss of 4.7B KRW, net loss of 5.3B KRW
R&D expenses of 2.6B KRW (797.5% of revenue), persistent operating losses
Cash and equivalents 8.1B KRW, short-term financial instruments 29.7B KRW (some liquidity)
Intangible assets 52.2B KRW, including 52B KRW construction in progress related to major shareholder CnP's business rights
Convertible bonds of 14.7B KRW (net), share count increasing due to conversions
Dengue fever treatment: Phase 2/3 clinical trial approved in Vietnam, first patient enrolled in April 2026
Prostate cancer treatment: domestic Phase 1 IND approved (Nov 2025)
COVID-19 treatment: domestic Phase 3 IND rejected; overseas trial preparation underway
Pancreatic cancer treatment: Phase 1 IND voluntarily withdrawn for redesign
Multiple license agreements with major shareholder CnP (52B KRW recognized as construction in progress)
No dividends or share buyback/cancellation
One pending lawsuit (claim amount 0.34B KRW)